BioLineRx Ltd. (NASDAQ:BLRX) Sees Significant Growth in Short Interest

BioLineRx Ltd. (NASDAQ:BLRX) was the target of a significant growth in short interest during the month of April. As of April 15th, there was short interest totalling 783,600 shares, a growth of 32.5% from the March 31st total of 591,500 shares. Based on an average daily volume of 432,700 shares, the days-to-cover ratio is currently 1.8 days.

BioLineRx Stock Performance

Shares of NASDAQ BLRX traded up $0.04 during trading hours on Friday, reaching $0.61. 582,908 shares of the stock were exchanged, compared to its average volume of 620,553. The firm has a market capitalization of $48.89 million, a price-to-earnings ratio of -0.68 and a beta of 1.38. The stock’s fifty day simple moving average is $1.01 and its 200 day simple moving average is $1.30. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.47 and a current ratio of 1.53. BioLineRx has a 52 week low of $0.55 and a 52 week high of $2.53.

BioLineRx (NASDAQ:BLRX) last posted its quarterly earnings data on Thursday, March 28th. The biotechnology company reported ($0.15) earnings per share for the quarter, topping the consensus estimate of ($0.22) by $0.07. The firm had revenue of $4.80 million for the quarter, compared to the consensus estimate of $0.17 million. During the same quarter in the previous year, the business earned ($0.09) EPS. Sell-side analysts predict that BioLineRx will post -1.03 EPS for the current year.

Wall Street Analyst Weigh In

Several research analysts recently commented on BLRX shares. StockNews.com raised BioLineRx to a “sell” rating in a research report on Tuesday, April 23rd. HC Wainwright reaffirmed a “buy” rating and set a $21.00 price target on shares of BioLineRx in a report on Wednesday, April 17th.

Institutional Trading of BioLineRx

A number of institutional investors have recently bought and sold shares of the business. PVG Asset Management Corp bought a new position in shares of BioLineRx during the fourth quarter worth approximately $97,000. Values First Advisors Inc. bought a new position in BioLineRx during the 3rd quarter worth $88,000. Rathbones Group PLC acquired a new position in BioLineRx in the 3rd quarter valued at $72,000. Allen Mooney & Barnes Investment Advisors LLC bought a new stake in shares of BioLineRx during the 3rd quarter valued at $46,000. Finally, B. Riley Wealth Advisors Inc. grew its holdings in shares of BioLineRx by 88.5% during the 3rd quarter. B. Riley Wealth Advisors Inc. now owns 21,300 shares of the biotechnology company’s stock worth $39,000 after purchasing an additional 10,000 shares in the last quarter. Institutional investors own 1.56% of the company’s stock.

BioLineRx Company Profile

BioLineRx Ltd., a pre-commercial-stage biopharmaceutical company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia.